Related Experiment Video
Updated: Aug 8, 2026

Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice
Published on: May 2, 2025
Inhibition and reversibility of renal changes: lessons from diabetic kidney disease
1Medical Department M (Diabetes and Endocrinology) and Clinical Institute, Aarhus University Hospital, Denmark. allan.flyvbjerg@dadlnet.dk
Unlabelled:
This review describes the clinical characteristics of kidney disease in patients with diabetes in terms of functional and morphological changes, and summarizes the risk factors for progression of disease and the knowledge available today on various treatment modalities. New insights into the pathogenesis of kidney disease in diabetic patients are also reviewed in the context of the nephropathy of Fabry disease. Newly recognized pathways that play a role in the development/progression of kidney disease in patients with diabetes include metabolic factors, (e.g. advanced glycation end products), intracellular signalling proteins (e.g. protein kinase C) and growth factors/cytokines (e.g. growth hormone, insulin-like growth factors, transforming growth factor beta and vascular endothelial growth factor). As classic examples of progress in our understanding of the pathogenesis of kidney disease in patients with diabetes, the relationship between two growth factor/cytokine-systems and the development of diabetic kidney disease is reviewed, including a description of well-known or potential therapeutic strategies targeting the two systems.
Conclusion:
It is hoped that the new pathogenetic insights into diabetic kidney disease may facilitate the development of new drugs for the treatment of this and related kidney diseases.
Related Concept Videos
Diabetic Nephropathy
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Chronic Kidney Disease III: Interprofessional Care
Chronic Kidney Disease I: Introduction
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
Antihypertensive Drugs: Direct Renin Inhibitors